Clinical Trial Update: A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

The CV-MG01 (Myasterix) trial for generalized myasthenia gravis has been withdrawn from Phase 2/Phase 3 development.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• CV-MG01 (Myasterix) (CV-MG01)

Snippet

Sponsor: CuraVac | Conditions: Myasthenia Gravis, Generalized | Phase 2, Phase 3 | Status: WITHDRAWN